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for Cardiac Catheterization Are Offset
by a Paradoxical Increase in the Rate
of Vascular Access Site Complications
With Femoral Access
The Campeau Radial ParadoxLorenzo Azzalini, MD, PHD, MSC,* Kunle Tosin, MD,* Malorie Chabot-Blanchet, MSC,y Robert Avram, MD,*
Hung Q. Ly, MD, MSC,* Benoit Gaudet, RN,* Richard Gallo, MD,* Serge Doucet, MD,* Jean-François Tanguay, MD,*
Réda Ibrahim, MD,* Jean C. Grégoire, MD,* Jacques Crépeau, MD,* Raoul Bonan, MD,* Pierre de Guise, MD,*
Mohamed Nosair, MD,* Jean-François Dorval, MD,* Gilbert Gosselin, MD,* Philippe L. L’Allier, MD,*
Marie-Claude Guertin, PHD,y Anita W. Asgar, MD,* E. Marc Jolicœur, MD, MSC, MHS*ABSTRACTOBJECTIVES The purpose of this study was to assess whether the beneﬁts conferred by radial access (RA) at an in-
dividual level are offset by a proportionally greater incidence of vascular access site complications (VASC) at a population
level when femoral access (FA) is performed.
BACKGROUND The recent widespread adoption of RA for cardiac catheterization has been associated with increased
rates of VASCs when FA is attempted.
METHODS Logistic regression was used to calculate the adjusted VASC rate in a contemporary cohort of consecutive
patients (2006 to 2008) where both RA and FA were used, and compared it with the adjusted VASC rate observed in a
historical control cohort (1996 to 1998) where only FA was used. We calculated the adjusted attributable risk to estimate
the proportion of VASC attributable to the introduction of RA in FA patients of the contemporary cohort.
RESULTS A total of 17,059 patients were included. At a population level, the VASC rate was higher in the overall
contemporary cohort compared with the historical cohort (adjusted rates: 2.91% vs. 1.98%; odds ratio [OR]: 1.48, 95%
conﬁdence interval [CI]: 1.17 to 1.89; p ¼ 0.001). In the contemporary cohort, RA patients experienced fewer VASC
than FA patients (adjusted rates: 1.44% vs. 4.19%; OR: 0.33, 95% CI: 0.23 to 0.48; p < 0.001). We observed a higher
VASC rate in FA patients in the contemporary cohort compared with the historical cohort (adjusted rates: 4.19% vs.
1.98%; OR: 2.16, 95% CI: 1.67 to 2.81; p < 0.001). This ﬁnding was consistent for both diagnostic and therapeutic
catheterizations separately. The proportion of VASCs attributable to RA in the contemporary FA patients was estimated
at 52.7%.
CONCLUSIONS In a contemporary population where both RA and FA were used, the safety beneﬁt associated with RA
is offset by a paradoxical increase in VASCs among FA patients. The existence of this radial paradox should be taken
into consideration, especially among trainees and default radial operators. (J Am Coll Cardiol Intv 2015;8:1854–64)
© 2015 by the American College of Cardiology Foundation.
AB BR E V I A T I O N S
AND ACRONYM S
CDCI = Charlson-Deyo
comorbidity index
CI = conﬁdence interval
ECI = Elixhauser comorbidity
index
FA = femoral access
OR = odds ratio
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1855R adial access (RA) for coronary angiographyand percutaneous coronary intervention(PCI) reduces bleeding complications related
to cardiac catheterization, and hence mortality, and
increases patient comfort (1–4). First described by Ca-
nadian cardiologist Lucien Campeau in 1989 (5), RA
has modernized the ﬁeld of interventional cardiology
and has become a popular approach for both trainees
and experienced operators.SEE PAGE 1865 PCI = percutaneous coronary
intervention
RA = radial access
VASC = vascular access site
complicationHistorically, cardiac catheterizations have been
performed via femoral access (FA). Although FA re-
mains necessary in multiple diagnostic and inter-
ventional settings, this technique has been associated
with vascular access site complication (VASC) rates
ranging from 2% to 6%, prolonged hospital stay, and
even deaths (6–10). A safe access to the femoral artery
can be jeopardized by obesity, severe atherosclerosis,
and anticoagulation. For these reasons, the femoral
puncture requires speciﬁc training and constant
practice.
Recently, an unusually high rate of VASC (12.5%)
has been observed in patients accessed via the
femoral artery by default radial operators (11). Thus,
although RA may reduce VASC rates at an individual
level, we hypothesized that RA can paradoxically be
associated with increased rates of complications at a
population level due to a greater number of VASCs in
FA patients (12). To address this important question,
we sought to calculate the proportion of VASCs
attributable to RA in a contemporary cohort of FA
patients.METHODS
Our evaluation covered 2 separate 2-year periods
and included consecutive patients admitted to
our tertiary-care teaching hospital who were re-
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historical control cohort, as only FA was used
(7). The contemporary cohort comprised pa-
tients from the second period (April 2006 to
March 2008), when our group transitioned
from FA to RA and both approaches were
used equally. Ethics approval was obtained
by the local institutional review board. As
this was a retrospective analysis conducted
per institutional guidelines for data security
and privacy, a waiver of consent was granted.
PATIENT POPULATION AND DATA COLLECTION.
Patients possibly had multiple catheteriza-
tions over the course of the study, but only 1
catheterization per patient was kept for the anal-
ysis. For patients with repeated catheterizations
over the course of the study, we classiﬁed patient-
catheterization pairs according to the following hi-
erarchy: catheterization complicated by a VASC >
ﬁrst catheterization. Moreover, diagnostic catheter-
izations followed by a therapeutic catheterization
within 30 days were considered as staged and
classiﬁed as therapeutic. When both RA and FA
were used during a single catheterization (either
because of a complex catheterization [e.g., high-risk
PCI performed through the RA, assisted by intra-
aortic balloon pump through the FA] or because of
access crossover), the access was either classiﬁed
according to the site through which the largest
sheath was used (in case of complex catheteriza-
tion) or according to the site through which the
catheterization was ﬁnalized (in case of crossover).
In particular, in case of radial-to-femoral crossover,
access site was classiﬁed as femoral.
Patient-speciﬁc baseline characteristics, hospital
data, comorbid conditions, and complications were
obtained from the discharge summary database,
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FIGURE 1 Study Population
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1856Régie de l’Assurance Maladie du Québec, our provin-
cial health administrative database. The discharge
summary database was populated by professional
medical archivists following a comprehensive review
of the medical charts of patients using the Interna-
tional Classiﬁcation of Diseases, 9th Revision for
patients in the historical cohort and the 10th Revi-
sion for those in the contemporary cohort. The reli-
ability and predictive capability of this approach in
cardiology has previously been validated (13–16).
Procedural details related to the cardiac catheteri-
zation for the contemporary cohort were abstracted
from the Mac-Lab catheterization laboratory soft-
ware (GE Healthcare, Little Chalfont, United
Kingdom), using MySQL (Oracle Corp., Redwood
Shores, California). Cross-tabulation of the different
databases was performed with SAS version 9.3 (SAS
Institute, Cary, North Carolina) using speciﬁcally
written code. Deterministic medical record linkage
was performed with the use of an encrypted unique
personal provincial health insurance number. Data
quality was ensured by veriﬁcation by three inde-
pendent investigators (L.A., K.T., and B.G.), as
detailed in the Online Appendix.
DEFINITION OF VASCULAR ACCESS SITE COMPLI-
CATIONS. As per standard institutional policies,
all patients are systematically followed-up for
30 days after hospital discharge by a specializednurse, who prospectively monitors and documents
the occurrence of all VASCs including: major hema-
toma, pseudoaneurysm, arteriovenous ﬁstula, retro-
peritoneal hematoma, arterial thrombosis, dissection
and perforation, distal embolization, femoral nerve
injury, local infection, and arterial avulsion, as pre-
viously reported (7). Detailed VASC deﬁnitions are
provided in the Online Appendix. VASCs were indi-
vidually recorded and were classiﬁed by their highest
level of severity.
STATISTICAL ANALYSIS. Baseline characteristics,
clinical presentation, procedural data, and VASCs
are presented by cohort and vascular access site.
Continuous variables are presented as mean  SD and
compared with the Student t test. Categorical vari-
ables are presented as frequency (percentages) and
compared using the chi-square test. For all tests,
p < 0.05 was considered signiﬁcant. Basic assump-
tions were veriﬁed before analysis. Analyses were
performed with SAS version 9.4 (SAS Institute, Cary,
North Carolina).
MODELING OF OUTCOMES. To estimate the propor-
tion of VASC attributable to RA in the contemporary
cohort of FA patients, we used the concept of attrib-
utable risk (17): 100  (Ie – Iu)/Ie; where Ie represents
the risk in those exposed ([number of events in
exposed patients]/[number of exposed patients]) and
TABLE 1 Baseline Characteristics and Comorbid Conditions
Historical Cohort Contemporary Cohort
p Value
Femoral
(n ¼ 6,922)
Femoral
(n ¼ 5,474)
Radial
(n ¼ 4,663)
Overall
(n ¼ 10,137)
Age, yrs 61.5  11.1 64.9  12.7 62.7  11.0 63.9  12.0 <0.001*
<0.001†
<0.001‡
Female 2,192 (31.7) 2,173 (39.7) 996 (21.4) 3,169 (31.3) 0.58*
<0.001†
<0.001‡
Body mass index, kg/m2 N/A 27.8  5.0 29.2  5.3 28.4  5.2 N/A*
N/A†
<0.001‡
Diabetes mellitus 1,082 (15.6) 1,350 (24.7) 1,169 (25.1) 2,519 (24.8) <0.001*
<0.001†
0.64‡
Dyslipidemia 2,103 (30.4) 3,232 (59.0) 3,231 (69.3) 6,463 (63.8) <0.001*
<0.001†
<0.001‡
Hypertension 1,900 (27.4) 2,902 (53.0) 2,679 (57.4) 5,581 (55.1) <0.001*
<0.001†
<0.001‡
Active smoking 893 (12.9) 991 (18.1) 1,228 (26.3) 2,219 (21.9) <0.001*
<0.001†
<0.001‡
Coronary artery disease 4,296 (62.1) 2,516 (46.0) 3,203 (68.7) 5,719 (56.4) <0.001*
<0.001†
<0.001‡
Peripheral artery disease 154 (2.2) 682 (12.5) 433 (9.3) 1,115 (11.0) <0.001*
<0.001†
<0.001‡
Stroke 233 (3.4) 183 (3.3) 102 (2.2) 285 (2.8) 0.04*
0.94†
<0.001‡
Heart failure 303 (4.4) 502 (9.2) 286 (6.1) 788 (7.8) <0.001*
<0.001†
<0.001‡
Chronic kidney disease 350 (5.1) 612 (11.2) 344 (7.4) 956 (9.4) <0.001*
<0.001†
<0.001‡
Elixhauser comorbidity index
0 2,764 (39.9) 861 (15.7) 908 (19.5) 1,769 (17.5) <0.001*
1 2,167 (31.3) 1,359 (24.8) 1,363 (29.2) 2,722 (26.9) <0.001†
2 1,169 (16.9) 1,296 (23.7) 1,109 (23.8) 2,405 (23.7) <0.001‡
3 or higher 822 (11.9) 1,958 (35.8) 1,283 (27.5) 3,241 (32.0)
Charlson-Deyo comorbidity index
0 3,038 (43.9) 1,762 (32.2) 1,387 (29.7) 3,149 (31.1) <0.001*
1 2,587 (37.4) 1,986 (36.3) 1,964 (42.1) 3,950 (39.0) <0.001†
2 824 (11.9) 894 (16.3) 792 (17.0) 1,686 (16.6) <0.001‡
3 or higher 473 (6.8) 832 (15.2) 520 (11.2) 1,352 (13.3)
Values are mean  SD or n (%), as appropriate. The p value comparisons: *historical vs. overall contemporary cohort; †historical vs. femoral contemporary cohort; ‡radial vs.
femoral contemporary cohort.
N/A ¼ not available.
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1857Iu represents the risk in those unexposed ([number of
events in unexposed patients]/[number of unexposed
patients]). Operationally, the risk attributable to RA
was estimated from the difference between the pro-
portion of VASCs in FA subjects of the contemporary
cohort (exposed to introduction of RA, Ie) and the
proportion of VASC in the historical (unexposed)
cohort (Iu), expressed as a fraction of the proportionof VASCs in FA subjects of the contemporary cohort
(Ie). Additional information is available in the Online
Appendix.
To control for confounding variables between
cohorts, VASC rates were adjusted using logistic
regression analysis with block entry of variables. The
principal model was built using the following
candidate independent variables: age, sex, period of
TABLE 2 Clinical Presentation and Procedural Data
Historical Cohort Contemporary Cohort
p Value
Femoral
(n ¼ 6,922)
Femoral
(n ¼ 5,474)
Radial
(n ¼ 4,663)
Overall
(n ¼ 10,137)
Clinical presentation
ST-segment elevation myocardial
infarction (primary and rescue PCI)
683 (9.9) 517 (9.4) 501 (10.7) 1,018 (10.0) 0.71*
0.43†
0.03‡
Cardiogenic shock 92 (1.3) 112 (2.0) 4 (0.1) 116 (1.1) 0.28*
0.002†
<0.001‡
Type of procedure
Diagnostic 3,254 (47.0) 3,016 (55.1) 2,328 (49.9) 5,344 (52.7) <0.001*
<0.001†
<0.001‡
Therapeutic 3,668 (53.0) 2,458 (44.9) 2,335 (50.1) 4,793 (47.3)
Procedural data
Access site crossover§ 0 319 (6.1) 12 (0.3) 331 (3.4) N/A*
N/A†
<0.001‡
Concomitant femoral vein puncture N/A 1,217 (23.2) 38 (0.8) 1,255 (12.8) N/A*
N/A†
<0.001‡
Sheath size
5-F or lower N/A 188 (3.6) 137 (3.0) 325 (3.4) N/A*
6-F N/A 4,791 (92.5) 4,392 (97.0) 9,183 (94.6) N/A†
7-F or higher N/A 198 (3.8) 1 (0.02) 199 (2.1) <0.001‡
Vascular closure device 0 1,632 (31.1) 4 (0.1) 1,636 (16.6) N/A*
N/A†
<0.001‡
Need for intra-aortic balloon pump 114 (1.6) 238 (4.3) 29 (0.6) 267 (2.6) <0.001*
<0.001†
<0.001‡
Anticoagulant agent
Heparin N/A 4,164 (79.4) 4,457 (96.9) 8,621 (87.6) N/A*
Bivalirudin N/A 39 (0.7) 42 (0.9) 81 (0.8) N/A†
None N/A 1,039 (19.8) 101 (2.2) 1,140 (11.6) <0.001‡
Glycoprotein IIb/IIIa inhibitors N/A 629 (12.0) 886 (19.3) 1,515 (15.4) N/A*
N/A†
<0.001‡
Values are n (%). The p value comparisons: *historical vs. overall contemporary cohort; †historical vs. femoral contemporary cohort; ‡radial vs. femoral contemporary cohort.
§Data presented in relation to the classiﬁcation used in the ﬁnal statistical model.
N/A ¼ not available; PCI ¼ percutaneous coronary intervention.
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1858the year (dichotomized as July to September vs.
October to June), number of cardiac catheterizations
during the index admission, ST-segment elevation
myocardial infarction, type of catheterization (diag-
nostic vs. therapeutic), and a comorbidity index. For
the latter predictor, we compared the discriminatory
performance of 2 indexes: the Charlson-Deyo co-
morbidity index (CDCI) (18,19) and the Elixhauser
comorbidity index (ECI) (20). Brieﬂy, the CDCI and
ECI infer clinical data from administrative coding of
discharge diagnoses. Taking into account 17 and 30
comorbidities, respectively, the CDCI and ECI
have been shown to correlate with in-hospital mor-
tality, length of stay, health care–related costs, as
well as medium- and long-term mortality (18–21).
Moreover, both have been validated and shown topredict in-hospital mortality in PCI patients (22).
Additional details are available in the Online
Appendix. The comorbidity index providing the
greater discrimination was selected in the ﬁnal
model. Model discrimination was evaluated with the
C-statistic. The ECI provided a greater discrimination
in the femoral cohorts subgroups and was therefore
selected in the ﬁnal model.
This model was used separately on 8 subgroups
of patients (historical cohort, contemporary FA
cohort, contemporary RA cohort, overall contempo-
rary cohort, diagnostic catheterizations in histor-
ical cohort, therapeutic catheterization in historical
cohort, diagnostic catheterizations in contemporary
FA cohort, and therapeutic catheterizations in con-
temporary FA cohort), and the probability of VASCs
TABLE 3 Vascular Access Site Complications
Historical Cohort Contemporary Cohort
p Value
Femoral
(n ¼ 6,922)
Femoral
(n ¼ 5,474)
Radial
(n ¼ 4,663)
Overall
(n ¼ 10,137)
Major hematoma 86 (1.24%) 208 (3.80%) 61 (1.31%) 269 (2.65%) <0.0001*
<0.0001†
<0.0001‡
Pseudoaneurysm 81 (1.17%) 16 (0.29%) 0 16 (0.16%) <0.0001*
<0.0001†
0.0002‡
Arterial thrombosis 12 (0.17%) 6 (0.11%) 1 (0.02%) 7 (0.07%) 0.04*
0.35†
0.09‡
Arterial dissection 3 (0.04%) 7 (0.13%) 0 7 (0.07%) 0.50*
0.10†
0.01‡
Arterial perforation 0 3 (0.05%) 1 (0.02%) 4 (0.04%) 0.10*
0.05†
0.40‡
Arteriovenous ﬁstula 9 (0.13%) 2 (0.04%) 0 2 (0.02%) 0.005*
0.08†
0.19‡
Retroperitoneal
hematoma
2 (0.03%) 12 (0.22%) 0 12 (0.12%) 0.05*
0.002†
0.001‡
Distal embolization 4 (0.06%) 1 (0.02%) 0 1 (0.01%) 0.07*
0.28†
0.36‡
Others§ 3 (0.04%) 1 (0.02%) 3 (0.06%) 4 (0.04%) 0.90*
0.44†
0.24‡
Total 200 (2.89%) 256 (4.68%) 66 (1.42%) 322 (3.18%) 0.29*
<0.0001†
<0.0001‡
Values are n (%). The p value comparisons: *historical vs. overall contemporary cohort; †historical vs. femoral
contemporary cohort; ‡radial vs. femoral contemporary cohort. §“Others” indicates arterial avulsion, femoral
nerve injury, and local infection.
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1859was estimated for an “average” patient from the his-
torical cohort. For each subgroup, the estimated
probability was calculated using the beta coefﬁcients
provided by the logistic regression performed on this
subgroup and the mean values (for continuous vari-
ables) and proportions (for categorical variables)
observed in the historical cohort for the covariates.
These estimated probabilities were then used in
place of Ie and Iu to calculate the adjusted
attributable risk. We performed several stratiﬁed
analyses: according to ECI subcategories, baseline
risk of VASCs, and propensity of undergoing
FA in the contemporary cohort (additional details
are provided in the Online Appendix). To allow
pairwise-adjusted comparisons of subgroups, we also
performed logistic regressions including the same
covariates, as well as their interaction with the group
variable (cohort or access site, depending on the
subgroups compared). Odds ratios (ORs) along with
95% conﬁdence intervals (CIs) and p values are
presented.
RESULTS
BASELINE CHARACTERISTICS, CLINICAL PRESENTATION,
AND PROCEDURAL DATA. Of the 17,059 patients
included in the analysis, 6,922 belonged to the his-
torical cohort, and 10,137 to the contemporary cohort
(Figure 1). In the contemporary cohort, 5,474 pa-
tients (54.0%) underwent FA and 4,663 patients
(46.0%) underwent RA. Patients in the contemporary
cohort were older and presented with a higher
burden of cardiovascular risk factors and comorbid
conditions compared with patients in the historical
cohort (Table 1). There were no differences in
the incidence of ST-segment elevation myocardial
infarction and cardiogenic shock between the 2 co-
horts (Table 2). However, a greater proportion of
patients underwent therapeutic catheterizations in
the historical cohort. Demographic and procedural
data for patients that experienced a VASC are
available in Online Table 1.
VASC RATES. The rates of VASCs in the historical
and overall contemporary cohorts were similar (un-
adjusted rates: 2.89% vs. 3.18%; p ¼ 0.29) (Table 3,
Figure 2A). After adjustment, the risk of VASCs for
contemporary patients was higher than for historical
patients (adjusted rates: 2.91% vs. 1.98%; adjusted
OR: 1.48, 95% CI: 1.17 to 1.89; p ¼ 0.001). In the
contemporary cohort, RA patients experienced
fewer VASCs compared with FA patients (unad-
justed rates: 1.42% vs. 4.68%; p < 0.001; adjusted
rates: 1.44% vs. 4.19%; adjusted OR: 0.33, 95% CI:0.23 to 0.48; p < 0.001). FA patients in the
contemporary cohort experienced more VASCs
compared with patients in the historical cohort
(unadjusted rates: 4.68% vs. 2.89%; p < 0.001;
adjusted rates: 4.19% vs. 1.98%; adjusted OR: 2.16,
95% CI: 1.67 to 2.81; p < 0.001). This difference was
driven by a higher incidence of major hematoma
(3.80% vs. 1.24%; p < 0.001) and retroperitoneal
hematoma (0.22% vs. 0.03%; p ¼ 0.002). The dif-
ference in the overall incidence of VASCs among FA
patients between the historical and contemporary
cohorts persisted in the sensitivity analysis where
diagnostic (adjusted OR: 2.30, 95% CI: 1.36 to 3.91;
p ¼ 0.002) and therapeutic (adjusted OR: 2.24,
95% CI: 1.64 to 3.06; p < 0.001) catheterizations
among FA patients were analyzed separately
(Figure 2B). Predictors of VASCs are presented in
Online Table 2.
THE FRACTION OF VASCS IN FA PATIENTS ATTRIB-
UTABLE TO RA. We estimated that 52.7% of VASCs in
contemporary FA patients were attributable to the
FIGURE 2 VASC Rates
(A) All catheterizations across historical versus contemporary (femoral, radial, and overall)
cohorts. (B) Diagnostic and therapeutic catheterizations separately (historical vs. femoral
contemporary cohorts). The p values refer to comparisons between unadjusted rates. Crude
rates are displayed in gray and adjusted rates are shown in black. The highest predictive
power among the 2 multivariate models tested for adjustment was obtained by the model
including demographics and clinical variables, as well as the Elixhauser comorbidity index
(C-statistic 0.74 in the historical cohort). VASC ¼ vascular access site complication.
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1860use of the RA. This means that, after multivariate
adjustment, 52.7% of the VASCs experienced in FA
patients of the contemporary cohort are attributable
to the emphasis on RA. Similar attributable risks
were obtained when analyzing diagnostic (55.8%)
and therapeutic (53.9%) catheterizations separately.
We further analyzed adjusted VASC rates and
adjusted attributable risk of VASC across ECI cate-
gories (Figure 3). Although VASC rates increased in
parallel with the ECI in the historical cohort, VASC
rates did not show such a consistent pattern in the
contemporary FA cohort. As a result, the attributable
risk of a VASC decreased from a maximal value of
66.3% in patients with ECI ¼ 0 (low comorbidity) to a
minimum of 15.7% in ECI $3 (high comorbidity).
Moreover, we performed a similar stratiﬁed analysis
according to the quartiles of VASC risk score, using
the model presented in Online Table 2B (Figure 4).
Similar to the analysis stratiﬁed by ECI categories,
the unadjusted attributable risk of VASCs decreased
from a maximum of 38.2% for subjects in the ﬁrst
quartile to a minimum of 11.5% for patients in the
fourth quartile. Finally, we stratiﬁed according to the
propensity of undergoing FA in the contemporary
cohort and compared the resulting VASC rates to the
one of the historical cohort (Figure 5); similar to the 2
other stratiﬁed analyses, the unadjusted attributable
risk of VASC was highest (51.0%) among subjects in
the ﬁrst quintile (i.e., with lowest propensity of
receiving FA).
DISCUSSION
In this study, we investigated the effects of the
introduction of RA on the occurrence of VASCs in a
contemporary cohort of patients undergoing cardiac
catheterization. We found that although RA reduced
VASC rates at an individual level, it was paradoxi-
cally associated with increased rates of complica-
tions at a population level when compared to
historical control subjects. The increased VASC rates
at a population level were driven by complications
in FA patients, which offset the beneﬁt associated
with RA. If indeed the RA is linked to an increase
in femoral VASCs, eliminating the RA would
potentially prevent up to 52.7% of VASCs in FA
patients. This ﬁnding has important clinical and
research implications, given the recent global shift
toward RA by practitioners previously using FA
(23,24).
The higher VASC rates seen with FA since the
introduction of RA cannot be entirely explained by
the case-mix unaccounted for between the historical
and the contemporary cohorts. We believe that a
FIGURE 3 VASC Stratiﬁed by Elixhauser Comorbidity Index
Adjusted rates and attributable risks of vascular access site complications (VASCs),
across Elixhauser comorbidity index categories in the historical vs. femoral contemporary
cohorts.
FIGURE 4 VASC Stratiﬁed by VASC Risk Score
Unadjusted rates and attributable risks of vascular access site complications (VASCs),
across VASC risk score quartiles in the historical versus femoral contemporary cohorts.
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1861radial paradox does exist for several reasons. First,
the higher VASC rates observed in contemporary FA
patients remained clinically meaningful and statisti-
cally signiﬁcant despite adjustment with an accurate
multivariate model (C-statistic 0.74 in the historical
cohort). Second, the attributable risk of VASCs
showed an inverse relationship with the number of
comorbid conditions (as quantiﬁed with the ECI),
with the greatest attributable risk of VASC (66.3%)
seen in patients with few comorbidities (ECI ¼ 0), and
the lowest attributable risk (15.7%) in patients with
multiple comorbidities (ECI $3). This evidence sug-
gests that the patients who most often experience the
radial paradox are those with fewer comorbidities.
Similar ﬁndings were observed when attributable risk
was analyzed by stratum of VASC risk score and ac-
cording to propensity of undergoing FA in the
contemporary cohort: the risk of a femoral VASC
attributable to RA was greatest in patients with the
lowest baseline risk of a VASC and in patients with the
lowest propensity of undergoing FA, that is, the pa-
tients with clinical characteristics for which the
operator would usually favor using RA. Third, our
ﬁndings were consistent in patients undergoing
diagnostic catheterizations. Although it may be
argued that therapeutic catheterization has markedly
changed over the decade that separated the 2 cohorts,
no such argument can be made for diagnostic cathe-
terization, which has remained similar through the
years. Moreover, because smaller sheath sizes were
used in the contemporary cohort, the results would
be more likely biased against the existence of a radial
paradox. Finally, our ﬁndings have recently been
alluded to by other groups who also observed un-
usually high rates of VASCs in FA patients. For
example, Raﬁe et al. (11) reported VASC rates of 12.5%
with FA among default radial operators in the United
Kingdom, where FA is reserved for challenging clin-
ical scenarios, in which both patient- and procedure-
related risk factors for bleeding are highly prevalent.
This phenomenon has also been hinted at by a recent
analysis of the U.S. National Cardiovascular Data
Registry, which reported that the risk of access site
bleeding in FA patients increased after the adoption
of RA by previously FA-only operators over a 3-year
period (from 5.6% to 6.4%). Interestingly, the risk of
FA site bleeding increased as a function of the relative
increase in RA adoption: from 6.3% in the very-low
adoption group (<2% of transradial PCIs), to 7.4% in
the high adoption group (w45% transradial PCIs)
(p < 0.001) (25).
In many centers, the majority of cardiac cathe-
terizations are performed through the RA (23).
In such settings, trainees and less experiencedoperators have been trained to master the RA, but
such operators are less accustomed to using the FA
(12). Operator experience is a key determinant of
outcomes for a wide range of medical procedures
(26–28). We speculate that the radial paradox stems
FIGURE 5 VASC Stratiﬁed by Propensity of Undergoing FA
Unadjusted rates and attributable risks of vascular access site complications (VASCs),
across quintiles of propensity score of undergoing femoral access in the contemporary
cohort, compared with the historical cohort.
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1862from operators’ reduced expertise in safely access-
ing the femoral artery. We further speculate that
modern radial operators reserve the FA for complex
PCIs in critical clinical scenarios. The situation be-
comes synergistically problematic when poorly
trained operators attempt challenging FAs. Although
the radial paradox could possibly be explained by
these hypotheses, they are not addressed by this
analysis and need to be the focus of further
research.
However, the topical debate on vascular access
for cardiac catheterization is further compounded
by the recent ﬁnding that the lowest rates of
bleeding complications and mortality in patients
undergoing FA are observed at high-volume radial
centers compared with low-volume radial (i.e.,
mostly femoral) institutions (29,30). This is not
surprising if we consider that high-volume radial
centers are most frequently academic institutions,
where expert interventionalists operate, new tech-
niques are most likely to be quickly adopted and
mastered, and state-of-the-art post-procedural care
is provided. These ﬁndings, together with our data,
indicate that, although the synergy between the loss
of skills in securing FA and the selection of FA for
challenging clinical scenarios has currently led to
higher rates of VASCs, the widespread adoption
of RA mitigated the adverse outcomes related
to FA. These observations underscore the com-
plexity of the issue and might contribute to the
identiﬁcation of adequate strategies to improve pa-
tient outcomes.Indeed, actions are needed to reduce the rate of
VASCs when FA is attempted. Fluoroscopy- (31) and
ultrasound-guided (32) puncture, bivalirudin (33),
and vascular closure devices (34) appear to be
feasible and effective strategies. Additionally, sys-
temic anticoagulation should only be administered
once the ascending aorta has been successfully
cannulated during an attempted radial catheteri-
zation to avoid puncturing the femoral artery in a
fully anticoagulated patient, if crossover to FA is
needed. We believe that educational programs
for trainees and young interventional cardiolo-
gists should take into consideration this radial
paradox in such a way to maximize exposure to
optimal FA technique. Such programs could include
formal teaching, focused workshops, and simu-
lators, as is currently done for RA (35). Finally,
maintaining a minimal FA volume could also be
recommended.
STUDY LIMITATIONS. First, this is a retrospective
study, with all the inherent bias ascribed to this type
of design. However, we used multivariate analysis to
minimize the effects of confounders, which showed
good discriminatory performance. Second, some
important potential sources of confounding were not
recorded in our database (e.g., individual operator
volume; patient creatinine and coagulation panel;
sheath size, concomitant femoral vein puncture,
anticoagulation, and glycoprotein IIb/IIIa inhibitors
in the historical cohort, and so on). Nevertheless, the
consistency of our ﬁndings in a sensitivity analysis
and the use of a validated comorbidity index (20–22)
should have minimized this issue. Finally, it could
be argued that the contemporary (2006 to 2008)
cohort does not represent more recent experience
with RA/FA and current clinical practice. This cohort
was selected in an effort to analyze the complex
phenomenon of transitioning from a femoral to a
radial program, which is now particularly relevant in
many countries. In fact, in many centers (particularly
those outside Europe and Canada) current experience
with RA is moderate. For example, RA is used for
>25% of PCIs at only w20% of U.S. catheterization
laboratories (25), for an overall use of just w16% (36).
Therefore, the use of RA in routine clinical practice
most closely resembles the scenario described in our
study.
CONCLUSIONS
We observed an increase in the rates of VASCs
when FA is performed in a large, all-comer contem-
porary cohort of patients undergoing diagnostic or
therapeutic cardiac catheterizations (where both RA
PERSPECTIVES
WHAT IS KNOWN? The femoral arterial puncture is a tactful
intervention that requires knowledge, skills, andpractice.After the
relatively recent widespread adoption of RA, FA is used less often.
WHAT IS NEW?We found that the rate of vascular complications
was higher in a contemporary cohort where both RA and FA was
used compared with a historical cohort where only FA was utilized.
Thiswas drivenby a higher rate of complications in femoral patients
of the contemporary cohort. In the contemporary cohort, the safety
beneﬁt associated with RA was offset by a paradoxical increase in
vascular complications among femoral patients. The existence of
this radial paradox should be taken into consideration, especially
among trainees and default radial operators.
WHAT IS NEXT? Additional studies should propose and test
effective measures to improve FA techniques and minimize
complication rates, thus improving patient clinical outcomes.
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1863and FA are used) compared with historical control
subjects. This increase of FA-related VASCs at a
population level offset the beneﬁt associated with RA
at a patient level. The existence of a radial paradox
should be taken into account, and appropriate actions
should be taken to improve patient outcomes when
FA is required.
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